In a notable study by Hu et al., a novel approach was introduced wherein FAP gene‐engineered tumour cell‐derived exosome‐like nanovesicles (eNVs‐FAP) were developed as a convenient and scalable tumour vaccine.53 The gene discussed is FAP; the disease is neoplasm.